Agonist antibody to MuSK protects mice from MuSK myasthenia gravis
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2408324121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Julien Oury und 10 weiteren Autor:innen. Beteiligte Einrichtung: Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute, New York University Medical School, New York, NY 10016. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Neuromuscular Junction, Receptors, Cholinergic, Myasthenia Gravis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS), Prinses Beatrix Spierfonds (Het Prinses Beatrix Spierfonds).
Abstract (Originalsprache)
Myasthenia gravis (MG) is a chronic and severe disease of the skeletal neuromuscular junction (NMJ) in which the effects of neurotransmitters are attenuated, leading to muscle weakness. In the most common forms of autoimmune MG, antibodies attack components of the postsynaptic membrane, including the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). MuSK, a master regulator of NMJ development, associates with the low-density lipoprotein-related receptor 4 (Lrp4) to form the signaling receptor for neuronal Agrin, a nerve-derived synaptic organizer. Pathogenic antibodies to MuSK interfere with binding between MuSK and Lrp4, inhibiting the differentiation and maintenance of the NMJ. MuSK MG can be debilitating and refractory to treatments that are effective for AChR MG. We show here that recombinant antibodies, derived from MuSK MG patients, cause severe neuromuscular disease in mice. The disease can be prevented by a MuSK agonist antibody, presented either prophylactically or after disease onset. These findings suggest a therapeutic alternative to generalized immunosuppression for treating MuSK MG by selectively and directly targeting the disease mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute, New York University Medical School, New York, NY 10016.
- Department of Neuroscience and Physiology, Neuroscience Institute, New York University School of Medicine, New York, NY 10016.
- argenx, Zwijnaarde 9052, Belgium.
- Department of Human Genetics, Leiden University Medical Centre, Leiden 2300 RC, The Netherlands.
- Department of Neurology, Leiden University Medical Centre, Leiden 2300 RC, The Netherlands.
ORCID-Profile: Dana L E Vergoossen, Bernhardt Vankerckhoven, Roeland Vanhauwaert, Maartje G Huijbers, Steven J Burden
Förderung
- NINDS NIH HHS
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- Prinses Beatrix Spierfonds (Het Prinses Beatrix Spierfonds)
- Argenx (Argenx SE)
- NIA NIH HHS
Zitieren
APA
Oury, J., Gamallo-Lana, B., Santana, L., Steyaert, C., Vergoossen, D. L. E., Mar, A. C., Vankerckhoven, B., Silence, K., Vanhauwaert, R., Huijbers, M. G., & Burden, S. J. (2024). Agonist antibody to MuSK protects mice from MuSK myasthenia gravis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2408324121
Vancouver
Oury J, Gamallo-Lana B, Santana L, Steyaert C, Vergoossen DLE, Mar AC, et al. Agonist antibody to MuSK protects mice from MuSK myasthenia gravis. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2408324121
BibTeX
@article{Oury2024,
author = {Oury, Julien and Gamallo-Lana, Begona and Santana, Leah and Steyaert, Christophe and Vergoossen, Dana L E and Mar, Adam C and Vankerckhoven, Bernhardt and Silence, Karen and Vanhauwaert, Roeland and Huijbers, Maartje G and Burden, Steven J},
title = {Agonist antibody to MuSK protects mice from MuSK myasthenia gravis},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2408324121}
}
EUVIMED